

1 **LOW VITAMIN K1 INTAKE IN HEMODIALYSIS PATIENTS**

2 **Maria Fusaro<sup>1\*</sup>, Claudia D'Alessandro<sup>2</sup>, Marianna Noale<sup>3</sup>, Giovanni Tripepi<sup>4</sup>, Mario Plebani<sup>5</sup>,**  
3 **Nicola Veronese<sup>6</sup>, Giorgio Iervasi<sup>1</sup>, Sandro Giannini<sup>7</sup>, Maurizio Rossini<sup>8</sup>, Giovanni Tarroni<sup>9</sup>,**  
4 **Sandro Lucatello<sup>10</sup>, Alberto Vianello<sup>11</sup>, Irene Santinello<sup>12</sup>, Luciana Bonfante<sup>12</sup>, Fabrizio**  
5 **Fabris<sup>7</sup>, Stefania Sella<sup>7</sup>, Antonio Piccoli<sup>12</sup>, Agostino Naso<sup>12</sup>, Daniele Ciurlino<sup>13</sup>, Andrea Aghi<sup>7</sup>,**  
6 **Maurizio Gallieni<sup>14</sup>, Adamasco Cupisti<sup>2</sup>**

7

8 We thank the **LOW VITAMIN K1 INTAKE IN HEMODIALYSIS PATIENTS** Study  
9 Investigators, who provided patient clinical care and collected clinical data. They were the following:

10 **Davide Miozzo, Silvia Lazzaris, Daniela Cambi, Mirella Zabeo, Francesco Barbisoni,**

11

12 Affiliations:

13 <sup>1\*</sup> Institute of Clinical Physiology, National Council of Research, Pisa, Italy;

14 <sup>2</sup> Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy;

15 <sup>3</sup> National Research Council (CNR), Neuroscience Institute, Padua, Italy

16 <sup>4</sup> Clinical Epidemiology and Physiopathology of Renal Diseases and Hypertension, CNR, Institute of  
17 Biomedicine, Reggio Calabria, Calabria, Italy;

18 <sup>5</sup> Laboratory Medicine Unit, Department of Medicine, University of Padua, Italy;

19 <sup>6</sup> Department of Medicine (DI-MED), Geriatric Section, University of Padua, Italy;

20 <sup>7</sup> Department of Medicine, Clinica Medica 1, University of Padova, Padova, Italy;

21 <sup>8</sup> Rheumatology Unit, Department of Medicine, University of Verona, Italy;

22 <sup>9</sup> Nephrology Unit, ULSS 1 Belluno, Italy;

23 <sup>10</sup> UOC Nephrology and dialysis, ULSS 13, Dolo, Italy;

24 <sup>11</sup> UOC Nephrology and dialysis, ULSS 2, Feltre, Italy;

25 <sup>12</sup> Nephrology Unit, University of Padua, Padua, Italy;

26 <sup>13</sup> Renal Unit, IRCCS Multimedica, Sesto San Giovanni, Milan, Italy.

27 <sup>14</sup> Nephrology and Dialysis Unit, Ospedale San Carlo Borromeo, Department of Clinical and  
28 Biomedical Sciences "Luigi Sacco", University of Milano – Italy;

29

30 **Corresponding Author:**

31 Maria Fusaro

32 Institute of Clinical Physiology,

33 National Council of Research,

34 Via G. Moruzzi 1, 56124, Pisa, PI, Italy.

35 [dante.lucia@libero.it](mailto:dante.lucia@libero.it)

36 **ABSTRACT**

37

38 **Background & Aims**

39 Vitamin K acts as a coenzyme in the  $\gamma$ -carboxylation of vitamin K-dependent proteins, including  
40 coagulation factors, osteocalcin, matrix Gla protein (MGP), and the growth arrest-specific 6  
41 (GAS6) protein. Osteocalcin is a key factor for bone matrix formation. MGP is a local inhibitor of  
42 soft tissue calcification. GAS6 activity prevents the apoptosis of vascular smooth muscle cells. Few  
43 data on vitamin K intake in chronic kidney disease patients and no data in patients on a  
44 Mediterranean diet are available. In the present study, we evaluate the dietary intake of vitamin K1  
45 in a cohort of patients undergoing hemodialysis.

46 **Methods**

47 In this multi-center controlled observational study, data were collected from 91 patients aged > 18  
48 years on dialysis treatment for at least 12 months and from 85 age-matched control subjects with  
49 normal renal function. Participants completed a food journal of seven consecutive days for the  
50 estimation of dietary intakes of macro- and micro-nutrients (minerals and vitamins).

51 **Results**

52 Compared to controls, dialysis patients had a significant lower total energy intake, along with a  
53 lower dietary intake of proteins, fats, carbohydrates, fibres, and of all the examined minerals (Ca, P,  
54 Fe, Na, K, Zn, Cu, and Mg). With the exception of vitamin B12, vitamins intake followed a similar  
55 pattern, with a lower intake in vitamin A, B1, B2, C, D, E, folates, K1 and PP. These finding were  
56 confirmed also when normalized for total energy intake or for body weight.

57 In respect to the adequate intakes recommended in the literature, the prevalence of a deficient  
58 vitamin K intake was very high (70% to 90%) and roughly double than in controls. Multivariate  
59 logistic model identified Vitamin A and iron intake as predictors of vitamin K deficiency

60 **Conclusions.**

61 Hemodialysis patients had a significantly low intake in vitamin K1, which could contribute to  
62 increase the risk of bone fractures and vascular calcifications. Since the deficiency of vitamin K  
63 intake seems to be remarkable, dietary counselling to HD patients should also address the adequacy  
64 of vitamin K dietary intake and bioavailability. Whether diets with higher amounts of vitamin K1 or  
65 vitamin K supplementation can improve clinical outcomes in dialysis patients remains to be  
66 demonstrated.

67

68 **Keywords**

69 Hemodialysis, dialysis, phylloquinone, menaquinone, diet, nutrition.

## 70 INTRODUCTION

71 Vitamin K is a fat-soluble vitamin, which includes a series of vitamers: phylloquinones (vitamin  
72 K1) and menaquinones (vitamin K2). Vitamin K1 is found mainly in green leafy vegetables while  
73 vitamin K2 is mainly synthesized by intestinal bacteria and is found in butter and fermented cheeses  
74 [1].

75 Vitamin K1 is the main source of vitamin K. Vegetables in particular contain relevant amounts of  
76 phylloquinone, although there is great variability in vitamin K1 content among different vegetables.  
77 Green leafy vegetables and cabbages have the highest content and contribute to 40-50% of total  
78 intake [2] while most of fruits, fruit juices and other vegetables, such as carrots and tomatoes, have  
79 a lower content. Since Vitamin K1 is fat-soluble, its intestinal absorption is higher when introduced  
80 with vegetable oils, as soy, cottonseed, canola or olive oil.

81 Compared to phylloquinone, the dietary contribution of menaquinones intake is markedly lower.  
82 Dietary sources of vitamin K2 are chicken, egg yolk, dairy products, fermented cheeses in  
83 particular, cow liver and natto, a Japanese food made from fermented soybeans, which has the  
84 highest vitamin K2 content.

85 Some investigators also suggested the hypothesis of a conversion of dietary phylloquinone in  
86 menaquinone-4 (MK-4): it was reported that MK-4 is present in tissues of animals fed with  
87 phylloquinone as a sole source of vitamin K [3]. Extra-hepatic tissues from rats were shown to  
88 contain more MK-4 after phylloquinone administration rather than after MK-4 administration. High  
89 concentration of MK-4 were also found in extra-hepatic human tissues [4, 5].

90 Vitamin K acts as a coenzyme in the  $\gamma$ -carboxylation of vitamin K-dependent proteins (VKDPs),  
91 including coagulation factors, osteocalcin (bone Gla protein, BGP), matrix Gla protein (MGP), and  
92 the growth arrest-specific 6 (GAS6) protein. BGP is produced by osteoblasts during bone matrix  
93 formation and its hydroxyapatite-binding capacity is dependent on the vitamin K  $\gamma$ -carboxylation.  
94 MGP is produced by osteoclasts, chondrocytes and vascular smooth muscle cells and is a local

95 inhibitor of soft tissue calcification. The  $\gamma$ -carboxylation determines MGP bioactivity in preventing  
96 vascular calcification [6]. In this context, GAS6 activity is also relevant since it prevents the  
97 apoptosis of vascular smooth muscle cells [7].

98 Up to now, no evidence exists for an average requirement of Vitamin K, and as a consequence the  
99 Recommended Daily Allowance (RDA) is not defined. Hence, an Adequate Intake (AI) has been set  
100 based on representative dietary intake data from healthy subjects. In the U.S.A., the Food and  
101 Nutrition Board at the Institute of Medicine recommends an AI of 120  $\mu\text{g}/\text{day}$  for men and 90  
102  $\mu\text{g}/\text{day}$  for women [8]. Instead, the Italian Society of Human Nutrition recommends an AI of 140  
103  $\mu\text{g}/\text{day}$  below 60 years of age and 170  $\mu\text{g}/\text{day}$  above 60 years [9].

104 When considering the AI for vitamin K, no distinction is made between the different forms. This  
105 can be justified by the fact that phylloquinone is the major form in the diet while menaquinones,  
106 collectively referred to as vitamin K2, contribute a relatively small amount to satisfying the human  
107 requirement for vitamin K.

108 A deficit of vitamin K, due to a low dietary intake, potentially leads to a low serum level of  
109 carboxylated Gla proteins (VKDPs) and therefore to an increased risk of vascular calcification and  
110 bone fractures [10].

111 In chronic kidney disease, vascular calcification and mineral and bone disorders are very common:  
112 the risk of hip fracture is four times higher and that of aortic calcification is twice higher than in the  
113 general population [11, 12]. Recent studies have demonstrated that low levels of vitamin K are  
114 predictors of hip and vertebral fractures, aortic calcification, and cardiovascular disease [11, 13].

115 Growing evidence indicates that hemodialysis (HD) patients are at high risk of vitamin K  
116 deficiency. To achieve a lower dietary load of potassium and phosphorus, patients with end stage  
117 renal disease limit foods representing main sources of vitamin K, especially phylloquinone [14-16].  
118 Regardless of its cause, vitamin K deficiency could worsen the fragile clinical status of this subset  
119 of patients in terms of cardiovascular disease and mineral bone disorders. Because data on vitamin

120 K intake in ESRD patients on a Mediterranean diet are lacking, in the present study we evaluate the  
121 dietary intake of vitamin K1 in a cohort of clinically stable patients undergoing maintenance HD.

122

123

## METHODS

### 124 *Participants*

125 This observational study, collecting information reflecting the usual clinical practice, is population  
126 based, multi-center and controlled. Demographics and clinical data were collected from the medical  
127 charts of patients aged  $\geq 18$  years on HD treatment for at least 12 months. Exclusion criteria were:  
128 life expectancy lower than 6 months, a history or evidence of malignancy (except for non-  
129 melanoma skin neoplasia), gastrointestinal diseases with malabsorption, liver insufficiency, acute  
130 infectious diseases, psychiatric illnesses, use of antibiotics in the week preceding the dietary  
131 questionnaire. Only 6 patients (7%) were using warfarin and they were not excluded. A control  
132 group was formed by people without chronic kidney diseases and comparable for age, gender and  
133 race; they were hospital employees, nurses, or patient's partners. All the participants gave their own  
134 informed consent to the study, which did not modify the patient's clinical management. The study is  
135 in accordance with the Helsinki Declaration.

136

### 137 *Dietary assessment*

138 With the aim of assessing the nutritional status, participants were asked to complete a food journal  
139 of seven consecutive days for the estimation of dietary intakes of macro- and micro-nutrients  
140 (minerals and vitamins) between 2013 and 2014. An individual food journal was given to each  
141 patient. An experienced operator provided all the necessary information for a correct compilation.  
142 The food journal reported a description of the type and amount of food and beverages consumed in  
143 the different meals or during all the days of the week.

144 When completed, the diary was handed back to the operator who interviewed the patients with the  
145 aim to accurately verify the data reported in the diary, making any needed corrections or

146 integrations. The actual amount of food consumed was recorded by weighing or through the use of  
147 photographic images of real size portions included in the Atlas Photo Food by the Scotti-Bassani  
148 Institute [17].

149 The processing of data collected from the diaries allowed to estimate the average daily intake of  
150 Vitamin K1, using data on the content of vitamin K1 supplied by the United States Department of  
151 Agriculture (USDA), referring to over 900 foods including foods also typical of the Mediterranean  
152 diet [18].

153 We also estimated the energy and nutrients intake, namely protein, carbohydrates, lipids,  
154 unsaturated fatty acids, saturated fats, cholesterol, calcium, phosphorus, magnesium, iron, zinc,  
155 copper, fiber, and vitamins A, C, B1, B2, PP, D. Data were obtained using the food composition  
156 Tables of the Italian National Institute of Nutrition and of the European Institute of Oncology  
157 Database Edition 2008 [19, 20]. The daily energy and nutrients intake were reported as daily average  
158 of the 7-day food records. When appropriate, intakes were normalized by body weight or energy  
159 intake. Adjustment for total energy intake is usually appropriate in epidemiologic studies to control  
160 for confounding, reduce extraneous variation, and predict the effect of dietary interventions [21].

161

### 162 *Statistical analysis*

163 Data are expressed as mean  $\pm$  standard deviation (SD), or median and inter-quartile range (Q1-Q3),  
164 for quantitative variables, and frequency percentages for discrete variables. Normal distribution of  
165 continuous variables was tested using the Shapiro-Wilk test.

166 The differential distribution for categorical variables among HD patients and controls was analyzed  
167 considering the  $\chi^2$  test or the Fisher's exact test. Quantitative variables were compared among  
168 groups of subjects (HD patients vs controls) considering the Generalized Linear Model (GLM),  
169 after testing for homoscedasticity (Levene's test) or the non-parametric Mann-Whitney test.

170 Associations between variables measured in the study and low vitamin K intake were analyzed by  
171 univariate and multivariate regression. Variables associated with the low vitamin K intake were



172 identified using univariate logistic regression. Any significant predictors with  $p \leq 0.10$  were then  
173 introduced into a multivariate model using the stepwise selection method. Statistical significance  
174 was assumed for  $p\text{-value} < 0.05$ . Analyses were carried out using SAS Software 9.3 (SAS Institute,  
175 Cary, NC, USA).

176

177

## RESULTS

178 Ninety-one HD patients and 85 healthy controls, comparable for age and gender, were included in  
179 the analysis (**Table 1**). Some features of the studied HD patient group are reported in Table 1: weight  
180 and BMI were significantly lower in patients than in controls.

181 **Table 2** shows the daily dietary intakes of macronutrients, minerals and vitamins. HD patients  
182 showed a significant lower total energy intake with a lower dietary intake of proteins, fats, fibres  
183 and carbohydrates compared to controls. HD patients had significantly lower dietary intake for all  
184 the examined minerals (Ca, P, Fe, Na, K, Zn, Cu, and Mg) than healthy controls (**Table 2**).

185 Vitamins intake followed a similar pattern, having HD patients significantly lower intake in vitamin  
186 A, B1, B2, C, D, E, folates, and PP, although no differences came to light for vitamin B12, as  
187 reported in **Table 2**. As a whole, HD patients ate less than controls, according to a lower body  
188 mass. However, differences in energy and protein intake are attenuated, but not blunted, when  
189 expressed as normalized by body weight (**Table 2**).

190 Similarly, HD patients showed an intake of vitamin K1 significantly lower than controls (**Table 3**).

191 This finding was confirmed also when normalized for total energy intake or for body weight (**Table**  
192 **3**). We also calculated vitamin K intake after exclusion of the 6 patients on warfarin treatment and  
193 results did not change.

194 Regarding the recommended intakes, an insufficient intake of vitamin K1 was more common in HD  
195 patients than in control subjects (**Table 4**). In respect to the AI suggested in 2001 by the National  
196 Research Council, the prevalence of a Vitamin K intake lower than recommended resulted very

197 high (89.2%) and roughly double than in controls. According to the Italian RDA value, a low  
198 Vitamin K intake was recorded in 71% of HD patients. Finally, when a cut-off value of 1 µg  
199 Vitamin K1 for kg of body weight is assumed [2], Vitamin K deficiency was observed in 49.5% of  
200 HD patients and in 24.7% of controls (p<0.001).

201 **Table 2** also shows low vitamin D intake for both groups, according to Italian RDA values.  
202 Multivariate logistic model identified Vitamin A and iron as predictors of vitamin K deficiency  
203 according to Italian RDA values (**Table 5**) and according to AI Dietary Reference Intakes of the  
204 Institute of Medicine (U.S.) Panel on Micronutrients. (**Table 6**). Comparison between the two  
205 multivariate regression logistic models is shown in **Table 7**.

206

207

208

## DISCUSSION

209 In this study, we assessed the dietary intake of Vitamin K1 in a group of stable patients with CKD  
210 undergoing maintenance HD. As a whole, the proportion of people with insufficient intake of  
211 vitamin K was approximately two fold in HD patients compared to healthy controls. Further  
212 adjustments for energy and body weight did not modify this finding. Our data showed that HD  
213 patients had a remarkable low vitamin K1 intake, since they reported a 2-fold lower median intake  
214 of dietary vitamin K1 than that suggested by RDAs for Italian population. This finding is in  
215 agreement with other observations that patients with chronic kidney disease undergoing HD are at  
216 high risk of vitamin K1 deficiency [14-16].

217 To the best of our knowledge, this is the only study available about dietary vitamin K intake in HD  
218 patients in a Mediterranean country, and including a control group. This is a relevant point since the  
219 study by Cranenburg et al. [14] was made in the Netherlands, where dietary habits are quite  
220 different from Mediterranean countries. The type of diet is an important aspect also in patients  
221 undergoing HD, considering that vitamin K is highly dependent from dietary habits. Oriental  
222 countries, for instance, have higher vitamin K intake due to a higher use of some foods, namely

223 cabbage kimchi, spinach, spring onions, and soybean oils, lacking in Western countries [22]. Our  
224 findings about HD patients are in agreement with previous reports, suggesting that HD patients  
225 introduce significantly less vitamin K1 than a reference population, independently from dietary  
226 habits [14]. A possible explanation of these findings is that haemodialysis patients on good  
227 nutritional status are advised to limit both sodium and potassium intake, the latter abundant in the  
228 same foods rich in vitamin K1, as green leafy vegetables [23]. This is in agreement with the low  
229 intake of fibres, vitamin A and C, and folate as well. A second possible explanation is that loss of  
230 appetite and food restrictions in the attempt to limit inter-dialysis weight gain are quite common in  
231 this population, affecting the total energy and nutrients intake [24]. In essence, they eat less and this  
232 fact is confirmed by the finding that HD patients had a significantly lower intake of macro- and  
233 micro-nutrients than controls. Although our data may seem underestimated, we believe that data  
234 collection was accurate and these data might reflect the real intake. Accordingly, our data are very  
235 similar to those reported by Martins et al [25] in elderly HD population (namely an energy intake of  
236  $18\pm 7$  vs.  $21\pm 8$  kcal/kg/day, and of protein  $0.8\pm 0.4$  vs.  $1.0\pm 0.4$  g/kg/day in HD and non-HD days,  
237 respectively). In addition, the Authors reported no differences in energy intake between HD and  
238 non-CKD elderly subjects. Therefore, the question arises as to whether a low nutrient intake really  
239 occurs in elderly subjects. [26]

240 No correlation was reported between vitamin K intake and markers of vitamin K status [14].  
241 However, markedly reduced vitamin K intake was also reported in a cohort of kidney transplant  
242 recipients with a median glomerular filtration rate of 61 ml/min, who did not have significant food  
243 intake limitations [27]. Total vitamin K intake was below the recommended level in 50% of patients  
244 and lower vitamin K intake was associated with less consumption of green vegetables.

245 Assessing the vitamin K status could be very important in HD patients because it has a key role in  
246 the activation of Gla-proteins involved in bone and tissue calcification. Mineral bone disorders and  
247 vascular calcifications are central issues in the management of chronic kidney disease. Vitamin K  
248 deficiency leads to an impairment in MGP and BGP activation and could indeed contribute to

249 worsening the cardiovascular and bone fracture risks in these patients [10]. In a multivariable-  
250 adjusted model, we identified Vitamin A (OR 0.996) and iron (OR 0.616) as predictors of vitamin  
251 K deficiency. Interestingly, another fat soluble vitamin, the vitamin A metabolite retinoic acid,  
252 down-regulates MGP gene expression in different rat and human cell lines [28], indicating that diet  
253 can have different effects on vitamin K-dependent proteins activity. Iron intake as predictor of  
254 vitamin K deficiency is a novel finding with no clear explanation, which should be further studied.  
255 The potential benefit of vitamin K supplementation has been shown in studies involving  
256 populations without kidney disease [29-30]. However, these studies have focused on the amount of  
257 vitamin K necessary for an adequate synthesis of blood coagulation factors, but not for the  
258 metabolism of the other vitamin K-dependent proteins, which might be different. Based on the  
259 current knowledge, our study confirms that supplementation is probably needed in HD patients, to  
260 achieve an optimal intake of vitamin K [31].

261 The main limitation of the study is that no specific determinations of vitamin K status and of  
262 VKDPs levels or activity (e.g. osteocalcin, MPG, INR) were performed, and that only estimation of  
263 VitK1 intake was reported. Conversely, the strength of our work is the presence of a control group,  
264 and the use of a 7-day dietary recall that was not used in previous investigations. There is great  
265 variability in the content of vitamin K1 in food, so short-term food journals are not suitable to gain  
266 reliable information and appropriate estimations. This is even more relevant in dialysis patients,  
267 whose diet is greatly influenced by dialysis treatments.

268 It is well known that a potential underestimation of energy and nutrients intake may occur using the  
269 food journal. Even if the food record analysis represent the most valid and simple tool for nutrients  
270 and calories estimation, the occurrence of a conscious or unconscious underreporting is largely  
271 known. We tried to limit this bias collecting an interview at the time of delivery of the 7-day food  
272 journal in order to verify, as described in the method section, the sizes of the portion, the type of  
273 food and any missing data. Furthermore, vitamin K1 and protein intake were normalized to the  
274 energy intake in order to limit the effect of a potential underestimation. Additional methods helping

275 in the assessment of energy and proteins intake, such as body weight changes over time before the  
276 dietary questionnaire and nPCR obtained from urea kinetics were not recorded in this study.  
277 The 7-day recall has been demonstrated to be more effective in collecting dietary habits in respect  
278 to other methods (i.e. 3-day recall) [32]. Dietary habits of HD patients may change significantly  
279 from dialysis to non dialysis day and in the weekend days, so the 7-day recall is particularly reliable  
280 to detect the average weekly intake of nutrients.

281 In conclusion, patients with chronic kidney disease undergoing haemodialysis had a  
282 significantly low intake in vitamin K1, which could contribute to increase the risk of bone fractures  
283 and vascular calcifications. Since the deficiency of vitamin K intake seems to be remarkable,  
284 dietary counselling to HD patients should also address the adequacy of vitamin K dietary intake and  
285 bioavailability. The retrospective nature of our study does not allow to adequately address all the  
286 issues related to vitamin K intake. In particular, data about nPCR and body weight fluctuations  
287 might be of importance to better understand the real dietary intake. In addition, we looked at  
288 vitamin K intake for the possible relationship with fractures and vascular calcifications in dialysis  
289 patients, but these clinical entities are complex and several other nutrients related to bone  
290 metabolism might be involved, such as calcium, phosphorus, vitamin A, vitamin K and vitamin D.

291 Looking at the relationship between nutrients intake (vitamin K and the other CKD-MBD  
292 related nutrients) and patient outcomes such as fractures and vascular calcification requires a larger  
293 patient population, possibly studied in a prospective study. Also, a randomized trial could allow  
294 evaluating whether diets with higher amounts of vitamin K1 or vitamin K supplementation can  
295 improve clinical outcomes in patients undergoing hemodialysis.

296 **References**

- 297 1. Shearer, M.J.; Newman, P. Metabolism and cell biology of vitamin K. *Thromb. Haemost.*  
298 **2008**, *100*, 530-547.
- 299 2. Booth, S.L.; Suttle, J.W. Dietary intake and adequacy of vitamin K. *J. Nutr.* **1998**, *128*, 785–  
300 788.
- 301 3. Sakamoto, N.; Kimura, M.; Hiraike, H.; Itokawa, Y. Changes of phylloquinone and  
302 menaquinone-4 concentrations in rat liver after oral, intravenous and intraperitoneal  
303 administration. *Int. J. Vitam. Nutr. Res.* **1996**, *66*, 322-328.
- 304 4. Thijssen, H.H.W.; Drittij-Reijnders, M. J. Vitamin K status in human tissues: tissue-specific  
305 accumulation of phylloquinone and menaquinone-4. *Br. J. Nutr.* **1996**, *75*, 121– 127.
- 306 5. Thijssen, H.H.W., Drittij-Reijnders, M. J.; Fischer, M.A.J.G. Phylloquinone and  
307 menaquinone-4 distribution in rats: synthesis rather than uptake determines menaquinone-4  
308 organ concentrations. *J. Nutr.* **1996**, *126*: 537– 543.
- 309 6. Vermeer, C. Vitamin K: the effect on health beyond coagulation - an overview. *Food. Nutr.*  
310 *Res.* **2012**, *56*.
- 311 7. Krueger, T.; Westenfeld, R.; Ketteler, M.; Schurgers, L.J.; Floege, J. Vitamin K deficiency  
312 in CKD patients: a modifiable risk factor for vascular calcification? *Kidney Int.* **2009**, *76*,  
313 18-22.
- 314 8. Institute of Medicine (US) Panel on Micronutrients. Recommended Dietary Intake for  
315 Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese,  
316 Molybdenum, Nickel, Silicon, Vanadium, and Zinc, 2001, National Academy Press,  
317 Washington, D.C.

- 318 9. SINU Società Italiana di Nutrizione Umana. *LARN - Livelli di Assunzione di Riferimento di*  
319 *Nutrienti ed energia per la popolazione italiana*. IV Revisione. SICS Ed, Milan, Italy, 2014;  
320 pp. 1-656.
- 321 10. Fusaro, M.; Crepaldi, G.; Maggi, S.; Galli, F.; D'Angelo, A; Calò, L.; Giannini, S.; Miozzo,  
322 D.; Gallieni, M. Vitamin K, bone fractures and vascular calcifications in chronic kidney  
323 disease: an important but poorly studied relationship. *J. Endocrinol. Invest.* **2011**, *34*, 317-  
324 323.
- 325 11. Rodriguez-Garcia, M.; Gomez –Alonso, C.; Naves-Diaz, M.; Diaz-Lopez, J.B.; Diaz-Corte,  
326 C.; Cannata-Andia, J.B. Asturias Study Group. Vascular calcifications, vertebral fractures  
327 and mortality in haemodialysis patients. *Nephrol. Dial. Transplant.* **2009**, *24*, 239-246.
- 328 12. Alem, A.M.; Sherrad, D.J.; Gillen, D.L.; Weiss, N.S.; Beresford, S.A.; Heckbert, S.R.;  
329 Wong, C.; Stehman-Breen, C. Increased risk of hip fracture among patients with end-stage  
330 renal disease. *Kidney Int.* **2006**, *70*, 1358-1366.
- 331 13. Fusaro, M.; Noale, M.; Viola, V.; Galli, F.; Tripepi, G.; Vajente, N.; Plebani, M.; Zaninotto,  
332 M.; Guglielmi, G.; Miotto, D.; Dalle Carbonare, L.; D'Angelo, A.; Naso, A.; Grimaldi, C.;  
333 Miozzo, D.; Giannini, S.; Gallieni, M.; for the VItamin K Italian (VIKI) Dialysis Study  
334 Investigators. Vitamin K, vertebral fractures, vascular calcifications and mortality: Vitamin  
335 K Italian (VIKI) Dialysis Study. *J. Bone Miner. Res.* **2012**, *27*, 2271-2278.
- 336 14. Craneburg, E.C.M.; Schurgers, L.J.; Uiterwijk, H.H.; Beulens, J.W.J.; Dalmeijer, G.W.;  
337 Westerhuis, R.; Magdeleyns, E.J.; Herfs, M.; Vermeer, C.; Laverman, G.D. Vitamin K  
338 intake and status are low in hemodialysis patients. *Kidney Int.* **2012**, *82*, 605-610.
- 339 15. Pilkey, R.M.; Morton, A.R.; Boffa, M.B.; Noordhof, C., Day, A.G.; Su, Y.; Miller, L.M.;  
340 Koschinsky, M.L.; Booth, S.L. Subclinical vitamin K deficiency in haemodialysis patients.  
341 *Am. J. Kidney Dis.* **2007**, *49*, 432-439.

- 342 16. Holden, R.M.; Morton, A.R.; Garland, JS.; Pavlov A.; Day A.G.; Booth, S.L. Vitamins K  
343 and D status in stages 3-5 chronic kidney disease. *Clin. J. Am. Soc. Nephrol.* **2010**, *22*, 387-  
344 395.
- 345 17. Fantuzzi, A.L.; Chiuchiù M.P.; Bedogni, G. *Atlante fotografico delle porzioni degli*  
346 *alimenti*. Istituto Scotti Bassani: Milano, Italy, 2005. <http://www.scottibassani.it/>
- 347 18. USDA National Nutrient Database for Standard Reference, Release 24, 2011,  
348 <http://ndb.nal.usda.gov/>
- 349 19. Tabelle di Composizione degli alimenti. INRAN. Edizione 1993  
350 [http://nut.entecra.it/646/tabelle\\_di\\_composizione\\_degli\\_alimenti.html](http://nut.entecra.it/646/tabelle_di_composizione_degli_alimenti.html)
- 351 20. Banca dati di composizione degli alimenti per studi epidemiologici in Italia. Istituto Europeo  
352 di Oncologia. Revisione del 2008. <http://www.bda-ieo.it/wordpress/en/>
- 353 21. Willett, W.C.; Howe, G.R.; Kushi, L.H. Adjustment for total energy intake in epidemiologic  
354 studies. *Am. J. Clin. Nutr.* **1997**, *65(4 Suppl)*, 1220S-1228S; discussion 1229S-1231S.
- 355 22. Kim, E.S.; Kim, M.S.; Na, W.R.; Sohn, C.M. Estimation of vitamin K intake in Koreans and  
356 determination of the primary vitamin K-containing food sources based on the fifth Korean  
357 National Health and Nutrition Examination Survey (2010-2011). *Nutr. Res. Pract.* **2013**, *7*,  
358 503-509.
- 359 23. Beto, J.A.; Bansal, V.K. Medical nutrition therapy in chronic kidney failure: integrating  
360 clinical practice guidelines. *J. Am. Diet. Assoc.* **2004**, *104*, 404-409.
- 361 24. Kopple, J.D.; Greene, T.; Chumlea, W.C.; Hollinger, D.; Maroni, B.J.; Merrill, D.; Scherch,  
362 L.K.; Schulman, G.; Wang, S.R.; Zimmer, G.S. Relationship between nutritional status and  
363 the glomerular filtration rate: results from the MDRD study. *Kidney Int.* **2000**, *57*, 1688-  
364 1703.



- 365 25. Martins A.M., Dias Rodrigues J.C., de Oliveira Santin FG, Barbosa Brito Fdos S, Moreira  
366 AS, Lourenço RA, Avesani CM. Food intake assessment of elderly patients on  
367 hemodialysis. *J Ren Nutr.* 2015 May;25(3):321-6).
- 368 26. Shapiro BB, Bross R, Morrison G, Kalantar-Zadeh K, Kopple JD. Self-Reported Interview-  
369 Assisted Diet Records Underreport Energy Intake in Maintenance Hemodialysis Patients. *J*  
370 *Ren Nutr.* 2015 Jul;25(4):357-63).
- 371 27. Boxma, P.Y.; van den Berg, E.; Geleijnse, J.M.; Laverman, G.D.; Schurgers, L.J.; Vermeer,  
372 C.; Kema, I.P.; Muskiet, F.A.; Navis, G.; Bakker, S.J.; de Borst, M.H. Vitamin K intake and  
373 plasma desphospho-uncarboxylated matrix Gla-protein levels in kidney transplant  
374 recipients. *PLoS One.* **2012**, *7*, e47991.
- 375 28. Kirfel, J.; Kelter, M.; Cancela, L.M.; Price, P.A.; Schüle, R. Identification of a novel  
376 negative retinoic acid responsive element in the promoter of the human matrix Gla protein  
377 gene. *Proc. Natl. Acad. Sci. U S A.* **1997**, *94*, 2227-32.
- 378 29. Schurgers, L.J.; Shearer, M.J.; Hamulyak, K.; Stocklin, E.; Vermeer, C. Effect of vitamin K  
379 intake on the stability of oral anticoagulant treatment: dose-response relationships in healthy  
380 subjects. *Blood* **2004**, *104*, 2682-2689.
- 381 30. Koos, R.; Mahnken, A.H.; Muhlenbruch, G.; Brandenburg, V.; Pflueger, B.; Wildberger,  
382 J.E.; Kühl, H.P. Relation of oral anticoagulation to cardiac valvular and coronary calcium  
383 assessed by multislice spiral computed tomography. *Am. J. Cardiol.* **2005**, *96*, 747-749.
- 384 31. Westenfeld, M.D.; Krueger, T.; Schlieper, G.; Cranenburg, E.C.M.; Magdeleyns, E.J.;  
385 Heidenreich, S.; Holzmann, S.; Vermeer, C.; Jahnen-Dechnet, W.; Ketteler, M.; Floege, J.;  
386 Schurgers, L.J. Effect of vitamin K2 supplementation on functional vitamin K deficiency in  
387 hemodialysis patients: a randomized trial. *Am. J. Kidney Dis.* **2012**, *59*, 186-195.

- 388 32. Dwyer, J.T. Dietary assessment. In *Modern Nutrition in health and disease*; Shils, M.E.;
- 389 Olson, J.A.; Shike, M., Eds.; Lea & Febiger, Philadelphia, USA, 1994: pp. 842-860.

390 **Table 1. Demographic data of the studied haemodialysis (HD) patients and controls.**

391 **Data are reported as mean  $\pm$  SD or median (Q1-Q3),**

392

	<b>HD patients (n=91)</b>	<b>Controls (n=85)</b>	<b>p-value<sup>§</sup></b>
Age, years	71 (52, 76)	69 (55, 75)	0,205 <sup>§</sup>
Gender – Males, n(%)	55 (60.4)	55 (64.7)	0,559 <sup>§</sup>
Weight, kg	70.7 $\pm$ 15.6	82.8 $\pm$ 14.7	<b>&lt; 0,0001*</b>
Height	1,66 $\pm$ 0,10	1.70 $\pm$ 0.9	<b>0,002*</b>
Body Mass Index, kg/m <sup>2</sup>	25.3 $\pm$ 5.2	28.7 $\pm$ 4.5	<b>0,001*</b>
Waist circumference, cm	97.3 $\pm$ 13.6	100.3 $\pm$ 13.1	0,308*
Dialysis vintage, months	93 (67 - 121)		
Dialysis technique type, n (%)			
1. Bicarbonate dialysis	29 (31.9)		
2. Hemofiltration	15 (16.5)		
3. Hemodiafiltration	24 (26.4)		
4. Acetate free biofiltration	12 (13.2)		
5. Others	11 (12.1)		
Previous transplantation, n (%)	11 (12.1)	-	-

393

394 **Table 2. Dietary intake of macronutrients, minerals and vitamins in haemodialysis (HD)**  
 395 **patients and in controls. Data are reported as mean  $\pm$  SD, or median (Q1-Q3).**

	<b>HD patients (n=91)</b>	<b>Controls (n=85)</b>	<b>p-value</b>
Total energy, Kcal/d	1442.8 (1292.0, 1442.8 )	1812 (1515.7, 2136.3 )	<b>&lt;0.0001</b>
Energy Intake Kcal/kg/d	22.32 $\pm$ 6.48	24.80 $\pm$ 6.35	<b>0.011</b>
Total protein, g/d	52.0 (43.9, 67.0 )	69.4 (58.4, 80.6)	<b>&lt;0.0001</b>
Protein/Weight, g/kg/d	0.82 (0.64, 0.97)	0.88 (0.77, 1.10)	<b>0.013</b>
Total fat, g/d	50.9 (40.1, 61.6 )	59.0 (49.7, 73.0)	<b>&lt;0.0001</b>
Carbohydrates, g/d	196.6 (168.7, 236.9 )	242.4 (203.1, 294.0)	<b>&lt;0.0001</b>
Fiber, g/d	12.0 (9.6, 13.7 )	19.6 (16.4, 23.3)	<b>&lt;0.0001</b>
Ca, mg/d	387.2 (264.9, 583.0 )	545.2 (418.2, 636.9)	<b>&lt;0.0001</b>
P, mg/d	755.9 (622.5, 922.5 )	1005.2 (826.1, 1179.2)	<b>&lt;0.0001</b>
Fe, mg/d	6.7 (5.6, 8.6)	8.8 (7.7, 10.7)	<b>&lt;0.0001</b>
Na mg/d	1206.3 (887.5, 1630.3)	1492.2 (938.7, 1833.4)	<b>0.003</b>
K, mg/d	1556.4 (1247.4, 2037.1 )	2514.5 (2158.8, 3191.1)	<b>&lt;0.0001</b>
Zn, mg/d	6.8 (5.3, 8.2)	8.0 (6.4, 10.5)	<b>&lt;0.0001</b>
Cu, mg/d	0.9 (0.6, 1.3)	1.2 (1.1, 2.3)	<b>&lt;0.0001</b>
Mg, mg/d	152.6 (120.7, 190.4)	200.1 (172.0, 267.6)	<b>&lt;0.0001</b>
Vit A, mcg/d	306.0 (130.6, 306.0)	460.8 (286.0, 566.7)	<b>&lt;0.0001</b>
Vit B1, mg/d	0.7 (0.58, 0.88)	0.84 (0.7, 1.1)	<b>&lt;0.0001</b>

Vit B2, mg/d	0.9 (0.7, 1.2)	1.3 (1.0, 1.4)	<b>&lt;0.0001</b>
Vit C, mg/d	47.3 (29.4, 67.8)	67.5 (52.4, 92.7)	<b>&lt;0.0001</b>
Vit D, µg/d	1.1 (0.8, 1.1)	1.6 (0.5, 2.4)	<b>0.029</b>
Vit E, µg/d	7.4 (5.5, 9.8)	11.5 (10.3, 13.7)	<b>&lt;0.0001</b>
Folates, µg/d	77.4 (57.9, 118.9)	141.2 (80.7, 181.0)	<b>&lt;0.0001</b>
PP, mg/d	10.2 (7.3, 12.9)	12.4 (8.9, 16.7)	<b>&lt;0.0001</b>

396

397 **Table 3. Dietary intake of Vitamin K1 in haemodialysis (HD) patients and in controls, as**  
398 **average total daily intake, or normalized per body weight and per 1000 Kcal energy intake**

399 **Data are reported as mean  $\pm$  SD, or median (Q1-Q3).**

	<b>HD patients</b> <b>(n=91)</b>	<b>Controls</b> <b>(n=85)</b>	<b>p-value</b>
<b>Vitamin K1, <math>\mu\text{g}/\text{d}</math></b>	71.6 (35.5, 117.1)	129.2 (61.5, 380.5)	<b>&lt;0.0001</b>
<b>Vitamin K1 <math>\mu\text{g}/\text{kg b.w.}</math></b>	1.00 (0.50, 2.22)	1.84 (1.00, 4.83)	<b>&lt;0.0001</b>
<b>Vitamin K1 <math>\mu\text{g}/1000\text{ Kcal}</math></b>	46.8 (25.1, 85.9)	88.9 (31.0, 210.2)	<b>&lt;0.0001</b>

400

401

402 **Table 4. Vitamin K intake in hemodialysis (HD) patients and in controls, according to**  
 403 **Recommended Dietary Allowance, Italy and AI Dietary Reference Intakes of the Institute of**  
 404 **Medicine (U.S.). Panel on Micronutrients**

405

	<b>HD patients (n=91)</b>	<b>Controls (n=85)</b>	<b>p-value</b>
<b>Recommended Dietary Allowance, Italy. 2012. [9]</b>			
< 60 yrs old: < 140 µg/die, n (%)	28 (30.8)	16 (18.8)	<b>&lt; 0.0001</b>
> 60 yrs old: < 170 µg/die, n (%)	44 (48.4)	22 (25.9)	
Total, n (%)	72 (89.2)	38 (44.7)	
<b>AI Dietary Reference Intakes of the Institute of Medicine (U.S.). Panel on Micronutrients, 2001. [8]</b>			
Men: < 120 µg/day, n (%)	41 (45.1)	27 (31.8)	<b>&lt; 0.0001</b>
Women: < 90 µg/day, n (%)	24 (26.4)	6 (7.1)	
Total, n (%)	65 (71.5)	33 (38.8)	

406 **Table 5. Logistic regression model for identifying predictors of vitamin K deficiency**  
 407 **according to Italian Recommended Dietary Allowance RDA values. Stepwise selection method**  
 408 **among significant variables ( $P < 0.10$ ) in the univariate model.**

Variable	Unadjusted models		Multivariable-adjusted models	
	OR (95% CI)	P-Value	OR (95% CI)	P-Value
Vit A, $\mu\text{g}/\text{d}$	0.994 (0.991, 0.997)	<b>&lt; 0.001</b>	0.996 (0.992, 0.999)	<b>0.022</b>
Vit C, $\text{mg}/\text{d}$	0.977 (0.964, 0.991)	<b>&lt; 0.001</b>	0.999 (0.971, 1.009)	0.305
Folates, $\mu\text{g}/\text{d}$	0.984 (0.974, 0.995)	<b>0.005</b>	0.991 (0.979, 1.004)	0.193
Ca, $\text{mg}/\text{d}$	0.996 (0.993, 0.999)	<b>0.004</b>	0.998 (0.993, 1.002)	0.288
Fe, $\text{mg}/\text{d}$	0.647 (0.503, 0.831)	<b>0.005</b>	0.616 (0.421, 0.901)	<b>0.013</b>

409



410 **Table 6. Logistic regression model for identifying predictors of vitamin K deficiency**  
 411 **according to AI Dietary Reference Intakes of the Institute of Medicine (U.S.) Panel on**  
 412 **Micronutrients. Stepwise selection method among significant variables (P < 0.10) in the**  
 413 **univariate model.**

414

Variable	Unadjusted models		Multivariable-adjusted models	
	OR (95% CI)	P-Value	OR (95% CI)	P-Value
Age, years	0.97 (0.937, 1.005)	0.089	0.993 (0.939, 1.051)	0,814
Cholesterol, mg/d	0.994 (0.988, 0.999)	<b>0.032</b>	1.003 (0.993, 1.006)	0,577
Ca, mg/d	0.997 (0.994, 1)	<b>0.027</b>	0.999 (0.995, 1.003)	0,507
Fe, mg/d	0.737 (0.599, 0.906)	<b>0.004</b>	0.661 (0.472, 0.927)	<b>0,016</b>
Vitamin A, µg /d	0.994 (0.991, 0.997)	<b>&lt; 0.001</b>	0.995 (0.991, 1)	<b>0,032</b>
Vitamin C, mg/d	0.978 (0.965, 0.991)	<b>0.001</b>	0.993 (0.974, 1.013)	0,486
Vitamin E µg/d	0.856 (0.762, 0.961)	<b>0.009</b>	1.05 (0.867, 1.271)	0,618
Folates, µg /d	0.985 (0.975, 0.995)	<b>0.004</b>	0.987 (0.97, 1.004)	0,136

415

416 **Table 7. Comparison between the two multivariate regression logistic models.**

Variable	LARN		AI Dietary	
	OR (95% CI)	P-Value	OR (95% CI)	P-Value
Age, years	/	/	0.993 (0.939, 1.051)	0,814
Vit A, µg /d	0.996 (0.992, 0.999)	<b>0.022</b>	0.995 (0.991, 1)	<b>0,032</b>
Vit C, mg/d	0.999 (0.971, 1.009)	0.305	0.993 (0.974, 1.013)	0,486
Vit E, µg /d	/	/	1.05 (0.867, 1.271)	0,618
Folates, µg /d	0.991 (0.979, 1.004)	0.193	1.026 (0.963, 1.094)	0,426
Ca, mg/d	0.998 (0.993, 1.002)	0.288	0.999 (0.995, 1.003)	0,507
Fe, mg/d	0.616 (0.421, 0.901)	<b>0.013</b>	0.661 (0.472, 0.927)	<b>0,016</b>
Cholesterol, mg/d	/	/	1.003 (0.993, 1.006)	0,577

417